Rituximab Biosimilar (Istituto Giannina Gaslini)

利妥昔单抗生物类似药(Istituto Giannina Gaslini)

Report date: 2022/09/29 11:27:37

Base Information

Drug NameRituximab Biosimilar (Istituto Giannina Gaslini)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsNephrotic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIstituto Giannina Gaslini
China Registration ClassN/A

Develop Information

Active CompaniesIstituto Giannina Gaslini
Inactive CompaniesN/A
Active IndicationsNephrotic Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A